Strategic Partnerships Molecure has actively pursued licensing and collaboration opportunities, evidenced by the exclusive licensing agreement with Ocean Biomedical in 2024, indicating a receptive posture toward external partnerships to advance pipeline programs and expand reach.

Clinical Progress Lead candidate OATD-01 progressing through trials with a completed Phase I in 2022 and a Phase II initiation in sarcoidosis in 2024, signaling near-term milestones and potential co-development or funded trial opportunities for related fibrotic and inflammatory indications.

Financing Momentum Recent growth funding and FDA clearance for pulmonary sarcoidosis trial in 2023, along with a $12M financing event, suggest a company with validated investor confidence and potential for strategic co-investment or milestone-driven deals.

Pipeline Focus Diversified seven-program pipeline centered on first-in-class small molecules targeting underexplored proteins and RNA functions, offering multiple entry points for collaboration across oncology, fibrosis, and inflammatory diseases with potential for共享 development deals.

Geographic and Capabilities Headquartered in Warsaw with additional labs in Łódź and expertise in medicinal chemistry, enabling scalable research partnerships, regional efficiency in collaboration terms, and potential access to EU-based funding and talent for sponsored programs.